OXS 3550

Drug Profile

OXS 3550

Alternative Names: 161533 TriKE; CD16/IL-15/CD33 - Oxis Biotech; CD16/IL-15/CD33 Tri-Specific Killer Engagers (TriKes); OXIS3550; OXS-3550-TriKE

Latest Information Update: 21 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Minnesota
  • Developer Oxis Biotech
  • Class Antibodies; Antineoplastics; Bispecific antibodies; Drug conjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical B cell lymphoma

Most Recent Events

  • 16 May 2018 GT Biopharma plans to file an IND application with the FDA in mid 2018
  • 24 Jan 2018 GT Biopharma plans FDA clinical trial in B-cell lymphoma in the second half of 2018
  • 01 Nov 2017 University of Minnesota plans a phase I/II trialfor Haematological malignancies (NCT03214666)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top